Recent developments in the treatment of inflammatory bowel disease - PubMed (original) (raw)
Review
Recent developments in the treatment of inflammatory bowel disease
Svend T Rietdijk et al. J Dig Dis. 2013 Jun.
Abstract
Crohn's disease and ulcerative colitis are chronic inflammatory bowel diseases that have been treated with corticosteroids, 5-aminosalicates and thiopurines, but therapeutic options have been broadened with the arrival of anti-tumor necrosis factor antibodies. In this article we reviewed the current evidence-based approach to inflammatory bowel disease, the modifications that have been made to existing therapies and discussed new drugs that have shown success in clinical trials. The new drugs discussed here are those that disturb lymphocyte homing to the gut (natalizumab, vedolizumab and anti-mucosal addressin cellular adhesion molecule); one that blocks interleukin (IL)-12 as well as the IL-23/T helper 17 (Th17) axis (ustekinumab) and one that blocks the signaling of multiple cytokines (tofacitinib).
© 2013 The Authors. Journal of Digestive Diseases © 2013 Wiley Publishing Asia Pty Ltd and Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine.
Similar articles
- [Current status of new drug development for inflammatory bowel diseases].
Kohgo Y, Tanabe H, Fujiya M. Kohgo Y, et al. Nihon Rinsho. 2012 Feb;70 Suppl 1:378-82. Nihon Rinsho. 2012. PMID: 23126121 Japanese. No abstract available. - Immunotherapy in inflammatory bowel disease.
Ahluwalia JP. Ahluwalia JP. Med Clin North Am. 2012 May;96(3):525-44, x. doi: 10.1016/j.mcna.2012.04.009. Med Clin North Am. 2012. PMID: 22703854 Review. - Biologic therapies in inflammatory bowel disease.
Cohen LB, Nanau RM, Delzor F, Neuman MG. Cohen LB, et al. Transl Res. 2014 Jun;163(6):533-56. doi: 10.1016/j.trsl.2014.01.002. Epub 2014 Jan 7. Transl Res. 2014. PMID: 24467968 Review. - Novel targets for inflammatory bowel disease therapeutics.
Löwenberg M, D'Haens G. Löwenberg M, et al. Curr Gastroenterol Rep. 2013 Feb;15(2):311. doi: 10.1007/s11894-012-0311-3. Curr Gastroenterol Rep. 2013. PMID: 23314806 Review. - Novel biologics in inflammatory bowel disease.
Papachristou GI, Plevy S. Papachristou GI, et al. Gastroenterol Clin North Am. 2004 Jun;33(2):251-69, ix. doi: 10.1016/j.gtc.2004.02.007. Gastroenterol Clin North Am. 2004. PMID: 15177537 Review.
Cited by
- Development of Inflammatory Bowel Disease Is Linked to a Longitudinal Restructuring of the Gut Metagenome in Mice.
Sharpton T, Lyalina S, Luong J, Pham J, Deal EM, Armour C, Gaulke C, Sanjabi S, Pollard KS. Sharpton T, et al. mSystems. 2017 Sep 5;2(5):e00036-17. doi: 10.1128/mSystems.00036-17. eCollection 2017 Sep-Oct. mSystems. 2017. PMID: 28904997 Free PMC article. - Dendritic cells in IBD pathogenesis: an area of therapeutic opportunity?
Bates J, Diehl L. Bates J, et al. J Pathol. 2014 Jan;232(2):112-20. doi: 10.1002/path.4277. J Pathol. 2014. PMID: 24122796 Free PMC article. - The microbiota in inflammatory bowel disease: current and therapeutic insights.
Lane ER, Zisman TL, Suskind DL. Lane ER, et al. J Inflamm Res. 2017 Jun 10;10:63-73. doi: 10.2147/JIR.S116088. eCollection 2017. J Inflamm Res. 2017. PMID: 28652796 Free PMC article. Review. - Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease.
Rumman A, Candia R, Sam JJ, Croitoru K, Silverberg MS, Steinhart AH, Nguyen GC. Rumman A, et al. Can J Gastroenterol Hepatol. 2017;2017:7365937. doi: 10.1155/2017/7365937. Epub 2017 Jan 23. Can J Gastroenterol Hepatol. 2017. PMID: 28239601 Free PMC article. - The Role of Fecal Microbiota Transplantation in the Treatment of Inflammatory Bowel Disease.
Stojek M, Jabłońska A, Adrych K. Stojek M, et al. J Clin Med. 2021 Sep 8;10(18):4055. doi: 10.3390/jcm10184055. J Clin Med. 2021. PMID: 34575166 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources